- $522.12m
- $50.73m
- $135.16m
- 51
- 30
- 13
- 22
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.07 | ||
| Price to Tang. Book | 1.07 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.86 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -31% | ||
| Return on Equity | -23.34% | ||
| Operating Margin | -114.36% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.85 | 200.58 | 53.91 | 91.37 | 135.16 | 50.11 | 116.11 | 178% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
Directors
- Lars Ekman NEC (71)
- Gene Kinney PRE (52)
- Tran Nguyen CFO (47)
- Brandon Smith COO (46)
- Karin Walker CAO (57)
- Wagner Zago CSO (48)
- Hideki Garren OTH (46)
- Carol Karp OTH (68)
- Radhika Tripuraneni OTH (41)
- Michael Malecek SEC (55)
- Sanjiv Patel DRC
- Paula Cobb IND (48)
- Richard Collier IND (67)
- Shane Cooke IND (58)
- K. Anders Harfstrand IND (64)
- Christopher Henney IND (80)
- Oleg Nodelman IND (44)
- Dennis Selkoe IND (77)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- September 26th, 2012
- Public Since
- December 21st, 2012
- No. of Shareholders
- 5,177
- No. of Employees
- 163
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 53,826,982
- Address
- 77 Sir John Rogersons Quay, DUBLIN, D02 T804
- Web
- https://www.prothena.com/
- Phone
- +353 12362500
- Auditors
- KPMG LLP
Upcoming Events for PRTA
Prothena Corporation PLC Annual Shareholders Meeting
Prothena Corporation PLC Annual Shareholders Meeting
Q2 2025 Prothena Corporation PLC Earnings Release
Similar to PRTA
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Prothena share price?
As of Today at 22:47 UTC, shares in Prothena are trading at $9.70. This share price information is delayed by 15 minutes.
How has the Prothena share price performed this year?
Shares in Prothena last closed at $9.70 and the price had moved by -52.82% over the past 365 days. In terms of relative price strength the Prothena share price has underperformed the S&P500 Index by -56.45% over the past year.
What are the analyst and broker recommendations for Prothena?
The overall consensus recommendation for Prothena is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Prothena dividend yield?
Prothena does not currently pay a dividend.
Does Prothena pay a dividend?
Prothena does not currently pay a dividend.
When does Prothena next pay dividends?
Prothena does not currently pay a dividend.
How do I buy Prothena shares?
To buy shares in Prothena you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Prothena?
As of the previous close price of $9.70, shares in Prothena had a market capitalisation of $522.12m.
Where are Prothena shares listed?
Here are the trading details for Prothena:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: PRTA
What kind of share is Prothena?
Based on an overall assessment of its quality, value and momentum Prothena is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Prothena share price forecast for 2025?
The analyst consensus target price for shares in Prothena is $51.75. That is 433.51% above the last closing price of $9.70.
Analysts covering Prothena currently have a consensus Earnings Per Share (EPS) forecast of -$3.61 for the next financial year.
Find out moreWhat is the trend in the Prothena share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Prothena. Over the past six months, its share price has underperformed the S&P500 Index by -33.18%.
As of the last closing price of $9.70, shares in Prothena were trading -41.13% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Prothena PE Ratio?
The Prothena PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $9.70.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Prothena?
Prothena's management team is headed by:
- Lars Ekman - NEC
- Gene Kinney - PRE
- Tran Nguyen - CFO
- Brandon Smith - COO
- Karin Walker - CAO
- Wagner Zago - CSO
- Hideki Garren - OTH
- Carol Karp - OTH
- Radhika Tripuraneni - OTH
- Michael Malecek - SEC
- Sanjiv Patel - DRC
- Paula Cobb - IND
- Richard Collier - IND
- Shane Cooke - IND
- K. Anders Harfstrand - IND
- Christopher Henney - IND
- Oleg Nodelman - IND
- Dennis Selkoe - IND